Study #2023-0237
A phase II study of response adapted ultra low dose 4 Gy radiation for definitive therapy of marginal zone Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Description
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase II
Physician name:
Jillian Gunther
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.